Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 3/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808923 | 0.86 | CYP4F2 (0.40) | PTGS1CYP4F2CYP4A11GPR132 | |
| SCHEMBL2808925 | 0.86 | CYP4F2 (0.40) | PTGS1CYP4F2CYP4A11GPR132 | |
| SCHEMBL12473747 | 0.74 | ABL1 (0.34) | — | |
| SCHEMBL2896682 | 0.73 | KDM4E (0.47) | PTGS1KDM4E | |
| SCHEMBL26334621 | 0.73 | PTGS1 (0.39) | PTGS1NPC1JAK2RAB9A | |
| SCHEMBL14856727 | 0.72 | CYP4F2 (0.33) | PTGS1CYP4F2CYP4A11 | |
| SCHEMBL185219 | 0.72 | KDM4E (0.53) | PTGS1GPR132KDM4EHSD17B10 | |
| SCHEMBL2805091 | 0.71 | PTGS1 (0.46) | PTGS1KDM4E | |
| SCHEMBL185415 | 0.71 | BDKRB1 (0.47) | GPR132PYGLKDM4EHSD17B10 | |
| SCHEMBL2414968 | 0.71 | SMYD3 (0.47) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539323-B3 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2539323-B3 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2539323-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2014-12-03 | — | — | EP | disclosed |
| EP-2539323-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2014-12-03 | — | — | EP | disclosed |
| US-8372838-B2 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| US-8372838-B2 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2011104203-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | PTGS1 182/4885CYP4F2 2566/4885CYP4A11 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.